Anti-(complement C5a) IgG4 chimeric monoclonal antibody ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 269 | Pyogenic arthritis | 1 |
269. Pyogenic arthritis
Clinical trials : 24 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-003273-21-PL (EUCTR) | 09/11/2020 | 08/09/2020 | NA | Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA). - Exploratory study of IFX-1 in Subjects with Pyoderma Gangrenosum | Pyoderma gangrenosum MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody | InflaRx GmbH | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 2 | United States;Poland |